Prestige Consumer Healthcare (NYSE:PBH) Upgraded by StockNews.com to “Buy” Rating

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Several other research firms have also recently issued reports on PBH. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. DA Davidson lifted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer increased their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $92.60.

Prestige Consumer Healthcare Trading Down 0.2 %

PBH opened at $83.71 on Tuesday. The business has a fifty day moving average price of $82.06 and a 200 day moving average price of $78.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $90.04. The stock has a market capitalization of $4.15 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 2.69 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Sell-side analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of the business. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth $84,932,000. Raymond James Financial Inc. purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $42,593,000. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $40,009,000. Bessemer Group Inc. grew its holdings in shares of Prestige Consumer Healthcare by 10,053.1% during the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after buying an additional 292,144 shares during the last quarter. Finally, Boston Trust Walden Corp increased its position in Prestige Consumer Healthcare by 43.5% in the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after acquiring an additional 252,089 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.